Regulatory metabolites of vitamin E and their putative relevance for atherogenesis

Redox Biology

Volumn 2, Issue 1, 2014, Pages 495-503

  Wallert, Maria ^a   Schmölz, Lisa ^a   Galli, Francesco ^b   Birringer, Marc ^c   Lorkowski, Stefan ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b UNIVERSITY OF PERUGIA   (Italy)

^c FULDA UNIVERSITY OF APPLIED SCIENCES   (Germany)

Author keywords

Atherosclerosis; Macrophage foam cells; 13' COOH; Tocopherol; Tocopherol long chain metabolites

Indexed keywords

ALPHA TOCOPHEROL; ALPHA TOCOPHEROL DERIVATIVE; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; ANTIOXIDANT; CHOLESTEROL; TOCOPHEROL;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; ENDOTHELIAL DYSFUNCTION; FOAM CELL; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LIPID OXIDATION; MACROPHAGE; NONHUMAN; PATHOPHYSIOLOGY; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTECTION; REVIEW; VITAMIN METABOLISM; ATHEROSCLEROTIC PLAQUE; BIOLOGICAL ACTIVITY; CARDIOVASCULAR DISEASE; CHEMOPROPHYLAXIS; CLINICAL TRIAL (TOPIC); LIPID HOMEOSTASIS; METABOLITE; OXIDATIVE STRESS; PATHOGENESIS; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; VITAMIN SUPPLEMENTATION; XENOBIOTIC METABOLISM; ANIMAL; BIOLOGICAL MODEL; BIOTRANSFORMATION; CHEMISTRY; ISOMERISM; LIVER; METABOLISM; OXIDATION REDUCTION REACTION; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIOXIDANTS; ATHEROSCLEROSIS; BIOTRANSFORMATION; CHOLESTEROL; CLINICAL TRIALS AS TOPIC; ENDOTHELIUM, VASCULAR; FOAM CELLS; HUMANS; INFLAMMATION; ISOMERISM; LIPOPROTEINS, LDL; LIVER; MODELS, BIOLOGICAL; OXIDATION-REDUCTION; TOCOPHEROLS; VITAMIN E;

EID: 84895505677     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2014.02.002     Document Type: Review

References (134)

1. Cullen P., Rauterberg J., Lorkowski S. The pathogenesis of atherosclerosis. Handb. Exp. Pharmacol. 2005, 170:3-70.
2. Monajemi H., Arkenbout E.K., Pannekoek H. Gene expression in atherogenesis. Thromb. Haemost. 2001, 86:404-412.
3. Jakubowski H. The pathophysiological hypothesis of homocysteine thiolactone-mediated vascular disease. J. Physiol. Pharmacol. 2008, 59(Suppl 9):155-167.
4. Raal F.J. Pathogenesis and management of the dyslipidemia of the metabolic syndrome. Metab. Syndr. Relat. Disord. 2009, 7:83-88.
5. Kullo I.J., Gau G.T., Tajik A.J. Novel risk factors for atherosclerosis. Mayo Clin. Proc. 2000, 75:369-380.
6. Mustacich D.J., Leonard S.W., Patel N.K., Traber M.G. Alpha-tocopherol beta-oxidation localized to rat liver mitochondria. Free Radic. Biol. Med. 2010, 48:73-81.
7. van Dam B., van Hinsbergh, Victor W.M., Stehouwer, Coen D.A., Versteilen A., Dekker H., Buytenhek R., Princen H.M., Schalkwijk C.G. Vitamin E inhibits lipid peroxidation-induced adhesion molecule expression in endothelial cells and decreases soluble cell adhesion molecules in healthy subjects. Cardiovasc. Res. 2003, 57:563-571.
8. Birringer M., Drogan D., Brigelius-Flohé R. Tocopherols are metabolized in HepG2 cells by side chain omega-oxidation and consecutive beta-oxidation. Free Radic. Biol. Med. 2001, 31:226-232.
9. Zhao Y., Lee M.-J., Cheung C., Ju J.-H., Chen Y.-K., Liu B., Hu L.-Q., Yang C.S. Analysis of multiple metabolites of tocopherols and tocotrienols in mice and humans. J. Agric. Food Chem. 2010, 58:4844-4852.
10. Schultz M., Leist M., Petrzika M., Gassmann B., Brigelius-Flohé R. Novel urinary metabolite of alpha-tocopherol, 2,5,7,8-tetramethyl-2(2'-carboxyethyl)-6-hydroxychroman, as an indicator of an adequate vitamin E supply?. Am. J. Clin. Nutr. 1995, 62:1527S-1534S.
11. Lebold K.M., Ang A., Traber M.G., Arab L. Urinary α-carboxyethyl hydroxychroman can be used as a predictor of α-tocopherol adequacy, as demonstrated in the energetics study. Am. J. Clin. Nutr. 2012, 96:801-809.
12. Galli F., Stabile A.M., Betti M., Conte C., Pistilli A., Rende M., Floridi A., Azzi A. The effect of α- and γ-tocopherol and their carboxyethyl hydroxychroman metabolites on prostate cancer cell proliferation. Arch. Biochem. Biophys. 2004, 423:97-102.
13. Grammas P., Hamdheydari L., Benaksas E.J., Mou S., Pye Q.N., Wechter W.J., Floyd R.A., Stewart C., Hensley K. Anti-inflammatory effects of tocopherol metabolites. Biochem. Biophys. Res. Commun. 2004, 319:1047-1052.
14. Betancor-Fernandez A., Sies H., Stahl W., Polidori M.C. In vitro antioxidant activity of 2,5,7,8-tetramethyl-2-(2'-carboxyethyl)-6-hydroxychroman (alpha-CEHC), a vitamin E metabolite. Free Radic. Res. 2002, 36:915-921.
15. Uto-Kondo H., Kiyose C., Ohmori R., Saito H., Taguchi C., Kishimoto Y., Machida N., Hasegawa M., Yoshioka E., Saita E., Hirata Y., Igarashi O., Kondo K. The coantioxidative effects of carboxyethyl-6-hydroxychromans and alpha-Tocopherol. J. Nutr. Sci. Vitaminol. 2007, 53:301-305.
16. Varga Z., Kosaras E., Komodi E., Katko M., Karpati I., Balla J., Paragh G., Aisa M.C., Galli F. Effects of tocopherols and 2,2'-carboxyethyl hydroxychromans on phorbol-ester-stimulated neutrophils. J. Nutr. Biochem. 2008, 19:320-327.
17. Wallert M., Mosig S., Rennert K., Funke H., Ristow M., Pellegrino R.M., Cruciani G., Galli F., Lorkowski S., Birringer M. Long-chain metabolites of α-tocopherol occur in human serum and inhibit macrophage foam cell formation in vitro. Free Radic. Biol. Med. 2013, 68:43-51.
18. Jiang Q., Yin X., Lill M.A., Danielson M.L., Freiser H., Huang J. Long-chain carboxychromanols, metabolites of vitamin E, are potent inhibitors of cyclooxygenases. Proc. Natl. Acad. Sci. USA 2008, 105:20464-20469.
19. Mazzini F., Betti M., Netscher T., Galli F., Salvadori P. Configuration of the vitamin E analogue garcinoic acid extracted from garcinia kola seeds. Chirality 2009, 21:519-524.
20. Birringer M., Lington D., Vertuani S., Manfredini S., Scharlau D., Glei M., Ristow M. Proapoptotic effects of long-chain vitamin E metabolites in HepG2 cells are mediated by oxidative stress. Free Radic. Biol. Med. 2010, 49:1315-1322.
21. Rodrigo R., Guichard C., Charles R. Clinical pharmacology and therapeutic use of antioxidant vitamins. Fundam. Clin. Pharmacol. 2007, 21:111-127.
22. Stampfer M.J., Hennekens C.H., Manson J.E., Colditz G.A., Rosner B., Willett W.C. Vitamin E consumption and the risk of coronary disease in women. N. Engl. J. Med. 1993, 328:1444-1449.
23. Yusuf S., Dagenais G., Pogue J., Bosch J., Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N. Engl. J. Med. 2000, 342:154-160.
24. Hercberg S., Galan P., Preziosi P., Bertrais S., Mennen L., Malvy D., Roussel A.-M., Favier A., Briançon S. The SU.VI.MAX study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch. Intern. Med. 2004, 164:2335-2342.
25. Gruppo Italiano per lo Studio della, Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Sopravvivenza nell'Infarto miocardico, Lancet 354, 1999, pp. 447-455.
26. Wright M.E., Lawson K.A., Weinstein S.J., Pietinen P., Taylor P.R., Virtamo J., Albanes D. Higher baseline serum concentrations of vitamin E are associated with lower total and cause-specific mortality in the alpha-tocopherol, beta-carotene cancer prevention study. Am. J. Clin. Nutr. 2006, 84:1200-1207.
27. Rapola J.M., Virtamo J., Ripatti S., Huttunen J.K., Albanes D., Taylor P.R., Heinonen O.P. Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet 1997, 349:1715-1720.
28. Virtamo J., Rapola J.M., Ripatti S., Heinonen O.P., Taylor P.R., Albanes D., Huttunen J.K. Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease. Arch. Intern. Med. 1998, 158:668-675.
29. Leppälä J.M., Virtamo J., Fogelholm R., Huttunen J.K., Albanes D., Taylor P.R., Heinonen O.P. Controlled trial of alpha-tocopherol and beta-carotene supplements on stroke incidence and mortality in male smokers. Arterioscler. Thromb. Vasc. Biol. 2000, 20:230-235.
30. Hirvonen T., Virtamo J., Korhonen P., Albanes D., Pietinen P. Intake of flavonoids, carotenoids, vitamins C and E, and risk of stroke in male smokers. Stroke 2000, 31:2301-2306.
31. Muntwyler J., Hennekens C.H., Manson J.E., Buring J.E., Gaziano J.M. Vitamin supplement use in a low-risk population of US male physicians and subsequent cardiovascular mortality. Arch. Intern. Med. 2002, 162:1472-1476.
32. Rimm E.B., Stampfer M.J., Ascherio A., Giovannucci E., Colditz G.A., Willett W.C. Vitamin E consumption and the risk of coronary heart disease in men. N. Engl. J. Med. 1993, 328:1450-1456.
33. Ascherio A., Rimm E.B., Hernán M.A., Giovannucci E., Kawachi I., Stampfer M.J., Willett W.C. Relation of consumption of vitamin E, vitamin C, and carotenoids to risk for stroke among men in the United States. Ann. Intern. Med. 1999, 130:963-970.
34. Frei B., Gaziano J.M. Content of antioxidants, preformed lipid hydroperoxides, and cholesterol as predictors of the susceptibility of human LDL to metal ion-dependent and -independent oxidation. J. Lipid Res. 1993, 34:2135-2145.
35. Vivekananthan D.P., Penn M.S., Sapp S.K., Hsu A., Topol E.J. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet 2003, 361:2017-2023.
36. Meydani M., Kwan P., Band M., Knight A., Guo W., Goutis J., Ordovas J. Long-term vitamin E supplementation reduces atherosclerosis and mortality in Ldlr-/-mice, but not when fed Western style diet. Atherosclerosis 2014, 233:196-205.
37. Cordero Z., Drogan D., Weikert C., Boeing H. Vitamin E and risk of cardiovascular diseases: a review of epidemiologic and clinical trial studies. Crit. Rev. Food Sci. Nutr. 2010, 50:420-440.
38. Asplund K. Antioxidant vitamins in the prevention of cardiovascular disease: a systematic review. J. Intern. Med. 2002, 251:372-392.
39. Marchioli R. Antioxidant vitamins and prevention of cardiovascular disease: laboratory, epidemiological and clinical trial data. Pharmacol. Res. 1999, 40:227-238.
40. Knekt P., Ritz J., Pereira M.A., O'Reilly E.J., Augustsson K., Fraser G.E., Goldbourt U., Heitmann B.L., Hallmans G., Liu S., Pietinen P., Spiegelman D., Stevens J., Virtamo J., Willett W.C., Rimm E.B., Ascherio A. Antioxidant vitamins and coronary heart disease risk: a pooled analysis of 9 cohorts. Am. J. Clin. Nutr. 2004, 80:1508-1520.
41. Eidelman R.S., Hollar D., Hebert P.R., Lamas G.A., Hennekens C.H. Randomized trials of vitamin E in the treatment and prevention of cardiovascular disease. Arch. Intern. Med. 2004, 164:1552-1556.
42. Shekelle P.G., Morton S.C., Jungvig L.K., Udani J., Spar M., Tu W., Suttorp M.J., Coulter I., Newberry S.J., Hardy M. Effect of supplemental vitamin E for the prevention and treatment of cardiovascular disease. J. Gen. Intern. Med. 2004, 19:380-389.
43. Law M.R., Morris J.K. By how much does fruit and vegetable consumption reduce the risk of ischaemic heart disease?. Eur. J. Clin. Nutr. 1998, 52:549-556.
44. Miller E.R., Pastor-Barriuso R., Dalal D., Riemersma R.A., Appel L.J., Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann. Intern. Med. 2005, 142:37-46.
45. Salonen J.T., Nyyssönen K., Salonen R., Lakka H.M., Kaikkonen J., Porkkala-Sarataho E., Voutilainen S., Lakka T.A., Rissanen T., Leskinen L., Tuomainen T.P., Valkonen V.P., Ristonmaa U., Poulsen H.E. Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study: a randomized trial of the effect of vitamins E and C on 3-year progression of carotid atherosclerosis. J. Intern. Med. 2000, 248:377-386.
46. Kostner K., Hornykewycz S., Yang P., Neunteufl T., Glogar D., Weidinger F., Maurer G., Huber K. Is oxidative stress causally linked to unstable angina pectoris? A study in 100 CAD patients and matched controls. Cardiovasc. Res. 1997, 36:330-336.
47. Stephens N.G., Parsons A., Schofield P.M., Kelly F., Cheeseman K., Mitchinson M.J. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996, 347:781-786.
48. Watkins M.L., Erickson J.D., Thun M.J., Mulinare J., Heath C.W. Multivitamin use and mortality in a large prospective study. Am. J. Epidemiol. 2000, 152:149-162.
49. El-Sohemy A., Baylin A., Spiegelman D., Ascherio A., Campos H. Dietary and adipose tissue gamma-tocopherol and risk of myocardial infarction. Epidemiology 2002, 13:216-223.
50. Bobák M., Brunner E., Miller N.J., Skodová Z., Marmot M. Could antioxidants play a role in high rates of coronary heart disease in the Czech Republic?. Eur. J. Clin. Nutr. 1998, 52:632-636.
51. Salonen J.T., Salonen R., Penttilä I., Herranen J., Jauhiainen M., Kantola M., Lappeteläinen R., Mäenpää P.H., Alfthan G., Puska P. Serum fatty acids, apolipoproteins, selenium and vitamin antioxidants and the risk of death from coronary artery disease. Am. J. Cardiol. 1985, 56:226-231.
52. Kok F.J., de Bruijn A.M., Vermeeren R., Hofman A., van Laar A., de Bruin M., Hermus R.J., Valkenburg H.A. Serum selenium, vitamin antioxidants, and cardiovascular mortality: a 9-year follow-up study in the Netherlands. Am. J. Clin. Nutr. 1987, 45:462-468.
53. Losonczy K.G., Harris T.B., Havlik R.J. Vitamin E and vitamin C supplement use and risk of all-cause and coronary heart disease mortality in older persons: the established populations for epidemiologic studies of the elderly. Am. J. Clin. Nutr. 1996, 64:190-196.
54. Knekt P., Reunanen A., Järvinen R., Seppänen R., Heliövaara M., Aromaa A. Antioxidant vitamin intake and coronary mortality in a longitudinal population study. Am. J. Epidemiol. 1994, 139:1180-1189.
55. Brown B.G., Zhao X.Q., Chait A., Fisher L.D., Cheung M.C., Morse J.S., Dowdy A.A., Marino E.K., Bolson E.L., Alaupovic P., Frohlich J., Albers J.J. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. 2001, 345:1583-1592.
56. Ito Y., Suzuki K., Ishii J., Hishida H., Tamakoshi A., Hamajima N., Aoki K. A population-based follow-up study on mortality from cancer or cardiovascular disease and serum carotenoids, retinol and tocopherols in Japanese inhabitants. Asian Pac. J. Cancer Prev. 2006, 7:533-546.
57. Lonn E., Bosch J., Yusuf S., Sheridan P., Pogue J., Arnold J., Malcolm O., Ross C., Arnold A., Sleight P., Probstfield J., Dagenais G.R. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 2005, 293:1338-1347.
58. Kushi L.H., Folsom A.R., Prineas R.J., Mink P.J., Wu Y., Bostick R.M. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N. Engl. J. Med. 1996, 334:1156-1162.
59. Nojiri S., Daida H., Mokuno H., Iwama Y., Mae K., Ushio F., Ueki T. Association of serum antioxidant capacity with coronary artery disease in middle-aged men. Jpn. Heart J. 2001, 42:677-690.
60. Mark S.D., Wang W., Fraumeni J.F., Li J.Y., Taylor P.R., Wang G.Q., Guo W., Dawsey S.M., Li B., Blot W.J. Lowered risks of hypertension and cerebrovascular disease after vitamin/mineral supplementation: the Linxian Nutrition Intervention Trial. Am. J. Epidemiol. 1996, 143:658-664.
61. Blot W.J., Li J.Y., Taylor P.R., Guo W., Dawsey S.M., Li B. The Linxian trials: mortality rates by vitamin-mineral intervention group. Am. J. Clin. Nutr. 1995, 62:1424S-1426S.
62. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial//MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:23-33.
63. Hense H.W., Stender M., Bors W., Keil U. Lack of an association between serum vitamin E and myocardial infarction in a population with high vitamin E levels. Atherosclerosis 1993, 103:21-28.
64. Sahyoun N.R., Jacques P.F., Russell R.M. Carotenoids, vitamins C and E, and mortality in an elderly population. Am. J. Epidemiol. 1996, 144:501-511.
65. Sesso H.D., Buring J.E., Christen W.G., Kurth T., Belanger C., MacFadyen J., Bubes V., Manson J.E., Glynn R.J., Gaziano J.M. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians[U+05F3] Health Study II randomized controlled trial. JAMA 2008, 300:2123-2133.
66. Klipstein-Grobusch K., Geleijnse J.M., den Breeijen J.H., Boeing H., Hofman A., Grobbee D.E., Witteman J.C. Dietary antioxidants and risk of myocardial infarction in the elderly: the Rotterdam Study. Am. J. Clin. Nutr. 1999, 69:261-266.
67. Riemersma R.A., Wood D.A., Macintyre C.C., Elton R.A., Gey K.F., Oliver M.F. Risk of angina pectoris and plasma concentrations of vitamins A, C, and E and carotene. Lancet 1991, 337:1-5.
68. Todd S., Woodward M., Tunstall-Pedoe H., Bolton-Smith C. Dietary antioxidant vitamins and fiber in the etiology of cardiovascular disease and all-causes mortality: results from the Scottish Heart Health Study. Am. J. Epidemiol. 1999, 150:1073-1080.
69. Boaz M., Smetana S., Weinstein T., Matas Z., Gafter U., Iaina A., Knecht A., Weissgarten Y., Brunner D., Fainaru M., Green M.S. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000, 356:1213-1218.
70. Ross R.K., Yuan J.M., Henderson B.E., Park J., Gao Y.T., Yu M.C. Prospective evaluation of dietary and other predictors of fatal stroke in Shanghai, China. Circulation 1997, 96:50-55.
71. Delport R., Ubbink J.B., Human J.A., Becker P.J., Myburgh D.P., Vermaak W.J. Antioxidant vitamins and coronary artery disease risk in South African males. Clin. Chim. Acta 1998, 278:55-60.
72. Rajasekhar D., Srinivasa Rao P.V.L.N., Latheef S.A.A., Saibaba K.S.S., Subramanyam G. Association of serum antioxidants and risk of coronary heart disease in South Indian population. Indian J. Med. Sci. 2004, 58:465-471.
73. Meraji S., Abuja P.M., Hayn M., Kostner G.M., Morris R., Oraii S., Tatzber F., Wonisch W., Zechner R., Gey K.F. Relationship between classic risk factors, plasma antioxidants and indicators of oxidant stress in angina pectoris (AP) in Tehran. Atherosclerosis 2000, 150:403-412.
74. Evans R.W., Shaten B.J., Day B.W., Kuller L.H. Prospective association between lipid soluble antioxidants and coronary heart disease in men. The Multiple Risk Factor Intervention Trial. Am. J. Epidemiol. 1998, 147:180-186.
75. de Gaetano G. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001, 357:89-95.
76. Keli S.O., Hertog M.G., Feskens E.J., Kromhout D. Dietary flavonoids, antioxidant vitamins, and incidence of stroke: the Zutphen study. Arch. Intern. Med. 1996, 156:637-642.
77. Feki M., Souissi M., Mokhtar E., Hsairi M., Kaabachi N., Antebi H., Alcindor L.G., Mechmeche R., Mebazaa A. Vitamin E and coronary heart disease in Tunisians. Clin. Chem. 2000, 46:1401-1405.
78. Ferns G., Williams J., Forster L., Tull S., Starkey B., Gershlick A. Cholesterol standardized plasma vitamin E levels are reduced in patients with severe angina pectoris. Int. J. Exp. Pathol. 2000, 81:57-62.
79. Cook N.R., Albert C.M., Gaziano J.M., Zaharris E., MacFadyen J., Danielson E., Buring J.E., Manson J.E. A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women[U+05F3]s Antioxidant Cardiovascular Study. Arch. Intern. Med. 2007, 167:1610-1618.
80. Lee I.-M., Cook N.R., Gaziano J.M., Gordon D., Ridker P.M., Manson J.E., Hennekens C.H., Buring J.E. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women[U+05F3]s Health Study: a randomized controlled trial. JAMA 2005, 294:56-65.
81. Kardinaal A.F., Kok F.J., Ringstad J., Gomez-Aracena J., Mazaev V.P., Kohlmeier L., Martin B.C., Aro A., Kark J.D., Delgado-Rodriguez M. Antioxidants in adipose tissue and risk of myocardial infarction: the EURAMIC Study. Lancet 1993, 342:1379-1384.
82. Goldstein J.L., Ho Y.K., Basu S.K., Brown M.S. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc. Natl. Acad. Sci. USA 1979, 76:333-337.
83. Schwartz C.J., Valente A.J., Sprague E.A., Kelley J.L., Nerem R.M. The pathogenesis of atherosclerosis: an overview. Clin. Cardiol. 1991, 14:I1-16.
84. Erwig L.-P., Henson P.M. Clearance of apoptotic cells by phagocytes. Cell Death Differ. 2008, 15:243-250.
85. Robbins C.S., Hilgendorf I., Weber G.F., Theurl I., Iwamoto Y., Figueiredo J.-L., Gorbatov R., Sukhova G.K., Gerhardt L.M., Louisa M.S., Smyth D., Zavitz Caleb C.J., Shikatani E.A., Parsons M., van Rooijen N., Lin H.Y., Husain M., Libby P., Nahrendorf M., Weissleder R., Swirski F.K. Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat. Med. 2013, 19:1166-1172.
86. Cushing S.D., Berliner J.A., Valente A.J., Territo M.C., Navab M., Parhami F., Gerrity R., Schwartz C.J., Fogelman A.M. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc. Natl. Acad. Sci. USA 1990, 87:5134-5138.
87. Collot-Teixeira S., Martin J., McDermott-Roe C., Poston R., McGregor J.L. CD36 and macrophages in atherosclerosis. Cardiovasc. Res. 2007, 75:468-477.
88. Newby A.C. Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler. Thromb. Vasc. Biol. 2008, 28:2108-2114.
89. Bäck M., Ketelhuth D.F., Agewall S. Matrix metalloproteinases in atherothrombosis. Prog. Cardiovas. Dis. 2010, 52:410-428.
90. Catalán U., Fernández-Castillejo S., Pons L., Heras M., Aragonés G., Anglès N., Morelló J.-R., Solà R. Alpha-tocopherol and BAY 11-7082 reduce vascular cell adhesion molecule in human aortic endothelial cells. J. Vasc. Res. 2012, 49:319-328.
91. Wu D., Koga T., Martin K.R., Meydani M. Effect of vitamin E on human aortic endothelial cell production of chemokines and adhesion to monocytes. Atherosclerosis 1999, 147:297-307.
92. Noguchi N., Hanyu R., Nonaka A., Okimoto Y., Kodama T. Inhibition of THP-1 cell adhesion to endothelial cells by alpha-tocopherol and alpha-tocotrienol is dependent on intracellular concentration of the antioxidants. Free Radic. Biol. Med. 2003, 34:1614-1620.
93. Berdnikovs S., Abdala-Valencia H., McCary C., Somand M., Cole R., Garcia A., Bryce P., Cook-Mills J.M. Isoforms of vitamin E have opposing immunoregulatory functions during inflammation by regulating leukocyte recruitment. J. Immunol. 2009, 182:4395-4405.
94. Nakamura Y.K., Omaye S.T. Alpha-tocopherol modulates human umbilical vein endothelial cell expression of Cu/Zn superoxide dismutase and catalase and lipid peroxidation. Nutr. Res. 2008, 28:671-680.
95. Uemura M., Manabe H., Yoshida N., Fujita N., Ochiai J., Matsumoto N., Takagi T., Naito Y., Yoshikawa T. Alpha-tocopherol prevents apoptosis of vascular endothelial cells via a mechanism exceeding that of mere antioxidation. Eur. J. Pharmacol. 2002, 456:29-37.
96. Nobata Y., Urakaze M., Temaru R., Sato A., Nakamura N., Yamazaki K., Kishida M., Takata M., Kobayashi M. alpha-Tocopherol Inhibits IL-8 synthesis induced by thrombin and high glucose in endothelial cells. Horm. Metab. Res. 2002, 34:49-54.
97. McCary C.A., Yoon Y., Panagabko C., Cho W., Atkinson J., Cook-Mills J.M. Vitamin E isoforms directly bind PKCα and differentially regulate activation of PKCα. Biochem. J. 2012, 441:189-198.
98. Li D., Saldeen T., Mehta J.L. Effects of alpha-tocopherol on ox-LDL-mediated degradation of IkappaB and apoptosis in cultured human coronary artery endothelial cells. J. Cardiovasc. Pharmacol. 2000, 36:297-301.
99. Ricciarelli R., Zingg J.M., Azzi A. Vitamin E reduces the uptake of oxidized LDL by inhibiting CD36 scavenger receptor expression in cultured aortic smooth muscle cells. Circulation 2000, 102:82-87.
100. Yasunari K., Kohno M., Kano H., Yokokawa K., Minami M., Yoshikawa J. Antioxidants improve impaired insulin-mediated glucose uptake and prevent migration and proliferation of cultured rabbit coronary smooth muscle cells induced by high glucose. Circulation 1999, 99:1370-1378.
101. Boscoboinik D., Szewczyk A., Azzi A. Alpha-tocopherol (vitamin E) regulates vascular smooth muscle cell proliferation and protein kinase C activity. Arch. Biochem. Biophys. 1991, 286:264-269.
102. Royer M.-C., Lemaire-Ewing S., Desrumaux C., Monier S., Pais de Barros, Jean-Paul, Athias A., Néel D., Lagrost L. 7-ketocholesterol incorporation into sphingolipid/cholesterol-enriched (lipid raft) domains is impaired by vitamin E: a specific role for alpha-tocopherol with consequences on cell death. J. Biol. Chem. 2009, 284:15826-15834.
103. Villacorta L., Graça-Souza A.V., Ricciarelli R., Zingg J.-M., Azzi A. Alpha-tocopherol induces expression of connective tissue growth factor and antagonizes tumor necrosis factor-alpha-mediated downregulation in human smooth muscle cells. Circ. Res. 2003, 92:104-110.
104. Ricciarelli R., Tasinato A., Clément S., Ozer N.K., Boscoboinik D., Azzi A. alpha-Tocopherol specifically inactivates cellular protein kinase C alpha by changing its phosphorylation state. Biochem. J. 1998, 334(Pt 1):243-249.
105. Azzi A., Boscoboinik D., Marilley D., Ozer N.K., Stäuble B., Tasinato A. Vitamin E: a sensor and an information transducer of the cell oxidation state. Am. J. Clin. Nutr. 1995, 62:1337S-1346S.
106. Clément S.A., Tan C.C., Guo J., Kitta K., Suzuki Y.J. Roles of protein kinase C and alpha-tocopherol in regulation of signal transduction for GATA-4 phosphorylation in HL-1 cardiac muscle cells. Free Radic. Biol. Med. 2002, 32:341-349.
107. Azzi A., Boscoboinik D., Clément S., Marilley D., Ozer N.K., Ricciarelli R., Tasinato A. Alpha-tocopherol as a modulator of smooth muscle cell proliferation. Prostaglandins Leukot. Essent. Fatty Acids 1997, 57:507-514.
108. Islam K.N., Devaraj S., Jialal I. alpha-Tocopherol enrichment of monocytes decreases agonist-induced adhesion to human endothelial cells. Circulation 1998, 98:2255-2261.
109. Devaraj S., Hugou I., Jialal I. Alpha-tocopherol decreases CD36 expression in human monocyte-derived macrophages. J. Lipid Res. 2001, 42:521-527.
110. Rode S., Rubic T., Lorenz R.L. alpha-Tocopherol disturbs macrophage LXRalpha regulation of ABCA1/G1 and cholesterol handling. Biochem. Biophys. Res. Commun. 2008, 369:868-872.
111. Teupser D., Thiery J., Seidel D. Alpha-tocopherol down-regulates scavenger receptor activity in macrophages. Atherosclerosis 1999, 144:109-115.
112. Kim S., Lee E.-H., Kim S.H., Lee S., Lim S.-J. Comparison of three tocopherol analogs as an inhibitor of production of proinflammatory mediators in macrophages. J. Pharmacol. Sci. 2012, 118:237-244.
113. Ng L.-T., Ko H.-J. Comparative effects of tocotrienol-rich fraction, α-tocopherol and α-tocopheryl acetate on inflammatory mediators and nuclear factor kappa B expression in mouse peritoneal macrophages. Food Chem. 2012, 134:920-925.
114. Lyons N.M., Woods J.A., O'Brien N.M. alpha-Tocopherol, but not gamma-tocopherol inhibits 7 beta-hydroxycholesterol-induced apoptosis in human U937 cells. Free Radic. Res. 2001, 35:329-339.
115. Vejux A., Guyot S., Montange T., Riedinger J.-M., Kahn E., Lizard G. Phospholipidosis and down-regulation of the PI3-K/PDK-1/Akt signalling pathway are vitamin E inhibitable events associated with 7-ketocholesterol-induced apoptosis. J. Nutr. Biochem. 2009, 20:45-61.
116. Rimbach G., Fischer A., Stoecklin E., Barella L. Modulation of hepatic gene expression by alpha-tocopherol in cultured cells and in vivo. Ann. N. Y. Acad. Sci. 2004, 1031:102-108.
117. Barella L., Muller P.Y., Schlachter M., Hunziker W., Stöcklin E., Spitzer V., Meier N., de Pascual-Teresa S., Minihane A.-M., Rimbach G. Identification of hepatic molecular mechanisms of action of alpha-tocopherol using global gene expression profile analysis in rats. Biochim. Biophys. Acta 1689, 2004:66-74.
118. Valastyan S., Thakur V., Johnson A., Kumar K., Manor D. Novel transcriptional activities of vitamin E: inhibition of cholesterol biosynthesis. Biochemistry 2008, 47:744-752.
119. Poirier J., Cockell K.A., Ratnayake W.M.Nimal, Scoggan K.A., Hidiroglou N., Gagnon C., Rocheleau H., Gruber H., Griffin P., Madère R., Trick K., Kubow S. Antioxidant supplements improve profiles of hepatic oxysterols and plasma lipids in butter-fed hamsters. Nutr. Metab. Insights 2010, 3:1-14.
120. González R., Collado J.A., Nell S., Briceño J., Tamayo M.J., Fraga E., Bernardos A., López-Cillero P., Pascussi J.M., Rufián S., Vilarem M.-J., De la Mata Manuel, Brigelius-Flohe R., Maurel P., Muntané J. Cytoprotective properties of alpha-tocopherol are related to gene regulation in cultured D-galactosamine-treated human hepatocytes. Free Radic. Biol. Med. 2007, 43:1439-1452.
121. Kluth D., Landes N., Pfluger P., Müller-Schmehl K., Weiss K., Bumke-Vogt C., Ristow M., Brigelius-Flohé R. Modulation of Cyp3a11 mRNA expression by alpha-tocopherol but not gamma-tocotrienol in mice. Free Radic. Biol. Med. 2005, 38:507-514.
122. Li W., Hellsten A., Jacobsson L.S., Blomqvist H.M., Olsson A.G., Yuan X.-M. Alpha-tocopherol and astaxanthin decrease macrophage infiltration, apoptosis and vulnerability in atheroma of hyperlipidaemic rabbits. J. Mol. Cell. Cardiol. 2004, 37:969-978.
123. Satchell L., Leake D.S. Oxidation of low-density lipoprotein by iron at lysosomal pH: implications for atherosclerosis. Biochemistry 2012, 51:3767-3775.
124. Williams R.J., Motteram J.M., Sharp C.H., Gallagher P.J. Dietary vitamin E and the attenuation of early lesion development in modified Watanabe rabbits. Atherosclerosis 1992, 94:153-159.
125. Praticò D., Tangirala R.K., Rader D.J., Rokach J., FitzGerald G.A. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. Nat. Med. 1998, 4:1189-1192.
126. Ozer N.K., Sirikçi O., Taha S., San T., Moser U., Azzi A. Effect of vitamin E and probucol on dietary cholesterol-induced atherosclerosis in rabbits. Free Radic. Biol. Med. 1998, 24:226-233.
127. Koga T., Kwan P., Zubik L., Ameho C., Smith D., Meydani M. Vitamin E supplementation suppresses macrophage accumulation and endothelial cell expression of adhesion molecules in the aorta of hypercholesterolemic rabbits. Atherosclerosis 2004, 176:265-272.
128. Axford-Gately R.A., Wilson G.J. Myocardial infarct size reduction by single high dose or repeated low dose vitamin E supplementation in rabbits. Can. J. Cardiol. 1993, 9:94-98.
129. Keaney J.F., Gaziano J.M., Xu A., Frei B., Curran-Celentano J., Shwaery G.T., Loscalzo J., Vita J.A. Low-dose alpha-tocopherol improves and high-dose alpha-tocopherol worsens endothelial vasodilator function in cholesterol-fed rabbits. J. Clin. Invest. 1994, 93:844-851.
130. Hasty A.H., Gruen M.L., Terry E.S., Surmi B.K., Atkinson R.D., Gao L., Morrow J.D. Effects of vitamin E on oxidative stress and atherosclerosis in an obese hyperlipidemic mouse model. J. Nutr. Biochem. 2007, 18:127-133.
131. Brigelius-Flohé R., Traber M.G. Vitamin E: function and metabolism. FEBS J. 1999, 13:1145-1155.
132. Brigelius-Flohé R., Kelly F.J., Salonen J.T., Neuzil J., Zingg J.-M., Azzi A. The European perspective on vitamin E: current knowledge and future research. Am. J. Clin. Nutr. 2002, 76:703-716.
133. Sontag T.J., Parker R.S. Cytochrome P450 omega-hydroxylase pathway of tocopherol catabolism. Novel mechanism of regulation of vitamin E status. J. Biol. Chem. 2002, 277:25290-25296.
134. Traber M.G. Mechanisms for the prevention of vitamin E excess. J. Lipid Res. 2013, 54:2295-2306.